Clinical Trial: SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187531) titled 'SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes' on Sept. 08.

Brief Summary: This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Type 1 Diabetes

Intervention: DRUG: High Dose SAB-142

High Dose SAB-142

DRUG: Low Dose SAB-142

Low Dose SAB-142

OTHER: Placebo

Placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: SAb Biotherapeuti...